Arcellx
Arcellx is a clinical-stage biotechnology company focused on reimagining cell therapy for cancer and incurable diseases. The company emphasizes innovation, collaboration, and a mission-driven culture aimed at developing safer, more effective, and accessible immunotherapies.
Arcellx is a biopharmaceutical company developing next‑generation cell therapies for cancer and autoimmune diseases. With a proprietary technology platform, they aim to reimagine and "supercharge" cell therapy to pursue cures and improve patient outcomes. The company advances engineered cell therapy candidates through research and clinical development to address unmet medical needs. Arcellx emphasizes innovation in therapeutic design and clinical translation.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Arcellx.
Arcellx didn’t post a salary, so this is our estimate from similar listings.
Gilead to buy Arcellx in nearly $8B deal
2 weeks ago
Manufacturing Associate II - Second Shift
Immatics
Scientist/Senior Scientist - T Cell Biology and T Cell Profiling in Autoimmune Disease
Shennon Biotechnologies Inc.
Principal Manufacturing Associate
Immatics
Associate, Cell Therapy Handling and Cryopreservation
Orca Bio
Associate, Cell Therapy Handling and Cryopreservation- Night Shift
Orca Bio
Manufacturing Associate, Cell Therapy
Amgen